CleanCap® Technology Platform

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc. operates as a crucial enabler for the biotechnology and pharmaceutical industries through its portfolio of companies that provide essential reagents, technologies, and testing services. The company's core offerings include TriLink BioTechnologies (nucleic acid production), Cygnus Technologies (biologics safety testing), and Maravai's proprietary CleanCap® mRNA capping technology. With a strong market position following its 2020 IPO, Maravai has capitalized on the mRNA revolution driven by COVID-19 vaccines while expanding into broader applications including gene therapies, cell therapies, and diagnostics.

Therapeutic Areas